CTX — Crescita Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$14.15m
- CA$5.90m
- CA$21.12m
Annual cashflow statement for Crescita Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.1 | 0.862 | -1.99 | -2.75 | -0.092 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.778 | 0.82 | 0.494 | 0.212 | -0.528 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.75 | -3.71 | 1.61 | 3.91 | 0.183 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -1.6 | -1.02 | 2.08 | 2.73 | 1.07 |
| Capital Expenditures | -0.346 | -0.229 | -0.133 | -1.19 | -0.333 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.5 | -0.061 | 0 | -0.834 | -0.64 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.846 | -0.29 | -0.133 | -2.02 | -0.973 |
| Financing Cash Flow Items | -0.05 | -0.05 | 0 | -0.1 | -0.05 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.5 | -1.85 | -0.782 | -0.861 | -0.788 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.95 | -3.09 | 1.15 | -0.112 | -0.696 |